Provided with the increasing number of patients diagnosed with ALS and the improved
societal awareness of the disease, more resources should be allocated to the research and …

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are severe
neurodegenerative disorders that belong to a common disease spectrum. The molecular …

Mutations in CHCHD10, coding for a mitochondrial intermembrane space protein, are a rare
cause of autosomal dominant amyotrophic lateral sclerosis. Mutation-specific toxic gain of …

Amaç: İskemik serebrovasküler hastalık geçirmiş bireylerin akut döneminde karotis intima
media kalınlığı (tCIM) ile gövde kontrolü arasındaki ilişkinin incelenmesidir. Gereç ve …

Many genes associated with familial forms of the amyotrophic lateral sclerosis (fALS) have
been identified in European and North American cohorts. However, little is known about the …

Introduction: The historical development, frequency, and impact of frontotemporal dementia
(FTD) are less clear in Latin America than in high-income countries. Although there is a …

Understanding patient clinical progression is a key gateway to planning effective clinical
trials and ultimately enabling bringing treatments to patients in need. In a rare disease like …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neuromuscular disease that has
a strong genetic component. Deleterious variants in the DCTN1 gene are known to be a …

Currently, there is no effective treatment for amyotrophic lateral sclerosis (ALS), despite the
limited efficacy of riluzole [1] and edaravone [2]. SOD1 (coding for the Cu/Zn superoxide …

Background: There is evolving evidence of non-uniform distribution of ALS worldwide, with
apparently lower incident and prevalent rates outside populations of European origin …